The Real Cost of Skipping Cancer Screening

Between 1975 and 2020, 5.94 million cancer deaths were averted in the US from five major cancers. What saved the most lives wasn't better treatment.

Source: NCI/CISNET, JAMA Oncology, December 2024

Smoking cessation alone saved 3.45 million lives from lung cancer. Screening saved another 1.3 million across breast, cervical, colorectal, and prostate cancers. Treatment advances, despite decades of investment, accounted for the remaining 20%.

This isn't an argument against treatment. It's a case for how much untapped value still sits in the screening side of the equation.

The dollar figure

A University of Michigan analysis quantified what the US loses from imperfect screening adherence. The gap between current screening rates and full compliance costs an estimated 3.2 to 5.1 million years of life collectively lost. Think of it this way: every person who dies from a cancer that could have been caught early loses decades. Added up across the entire US population, that's millions of years of life that didn't have to be lost, valued at $1.7 to $2.7 trillion.

Where the biggest return is

Not all screening gaps carry equal weight. CISNET modeling found that a 10-percentage-point increase in uptake would prevent 11,070 deaths from colorectal cancer, 1,790 from breast cancer, 1,710 from cervical cancer, and 1,010 from lung cancer over the lifetimes of newly screened individuals.

Colorectal screening offers the single highest return because the gap is wide (only 37.1% of adults 45-49 are screened) and the survival difference is steep (91% early vs 15% late).

It's bigger in China

If the US loses $1.7 to $2.7 trillion from imperfect screening with rates of 37-80% across major cancers, the loss in China, where over 530 million eligible adults remain almost entirely unscreened, is likely an order of magnitude larger.

Closing the gap starts with knowing what screenings apply to you. fixyou.app gives you a personalized plan in under 2 minutes. Free, in English and Chinese.